Clinical Trial Update: A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating infliximab (Remicade) for juvenile idiopathic arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: Centocor, Inc. | Conditions: Rheumatoid Arthritis, Juvenile | Phase 3 | Status: COMPLETED